New pill could cut transfusions for thalassemia patients

NCT ID NCT06302491

Recruiting now Disease control Sponsor: Kind Pharmaceuticals LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 study tests an oral drug called AND017 in 64 people with β-thalassemia, a blood disorder that often requires regular transfusions. Half the participants get the drug, half get a placebo, and everyone continues standard care. The goal is to see if AND017 is safe and can raise hemoglobin levels, potentially reducing transfusion needs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AND017 capsules
What this could lead to: If successful, AND017 could reduce the need for blood transfusions in people with β-thalassemia by boosting hemoglobin levels.
What could go wrong: This is an early Phase 2 trial with only 64 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HBS/Β-THALASSEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

beta thalassemia hemoglobin E-beta-thalassemia syndrome sickle cell-beta-thalassemia disease syndrome thalassemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THALASSEMIA

Contacts and locations

Locations

Guangxi Medical University No.1 Affiliated Hospital
RECRUITING

Nanning, Guangxi, 530021, China
Hainan General Hospital
RECRUITING

Haikou, Hainan, 570203, China
Liuzhou People's Hospital
RECRUITING

Liuzhou, Guangxi, 545006, China
Maoming People's Hospital
RECRUITING

Maoming, Guangdong, 525000, China
Nanfang Hospital Southern Medical University
NOT_YET_RECRUITING

Guangzhou, Guangdong, 510515, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.